MX2015014249A - Formulaciones de oxabicicloheptanos y oxabicicloheptenos. - Google Patents

Formulaciones de oxabicicloheptanos y oxabicicloheptenos.

Info

Publication number
MX2015014249A
MX2015014249A MX2015014249A MX2015014249A MX2015014249A MX 2015014249 A MX2015014249 A MX 2015014249A MX 2015014249 A MX2015014249 A MX 2015014249A MX 2015014249 A MX2015014249 A MX 2015014249A MX 2015014249 A MX2015014249 A MX 2015014249A
Authority
MX
Mexico
Prior art keywords
oxabicycloheptenes
oxabicycloheptanes
formulations
pp2a
inhibitor
Prior art date
Application number
MX2015014249A
Other languages
English (en)
Inventor
John S Kovach
Mickey L Wells
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of MX2015014249A publication Critical patent/MX2015014249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende un inhibidor de proteína fosfatasa 2A (PP2A) y glutamato monosódico.
MX2015014249A 2013-04-09 2014-04-08 Formulaciones de oxabicicloheptanos y oxabicicloheptenos. MX2015014249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361810053P 2013-04-09 2013-04-09
PCT/US2014/033317 WO2014168941A1 (en) 2013-04-09 2014-04-08 Formulations of oxabicycloheptanes and oxabicycloheptenes

Publications (1)

Publication Number Publication Date
MX2015014249A true MX2015014249A (es) 2016-06-02

Family

ID=51689953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014249A MX2015014249A (es) 2013-04-09 2014-04-08 Formulaciones de oxabicicloheptanos y oxabicicloheptenos.

Country Status (13)

Country Link
US (3) US10532050B2 (es)
EP (1) EP2983661B1 (es)
JP (1) JP2016516772A (es)
KR (1) KR20160004299A (es)
CN (1) CN105209036B (es)
AU (1) AU2014251087B2 (es)
BR (1) BR112015025852A2 (es)
CA (1) CA2909160C (es)
EA (1) EA201591931A1 (es)
HK (1) HK1221416A1 (es)
MX (1) MX2015014249A (es)
PH (1) PH12015502331A1 (es)
WO (1) WO2014168941A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CN104619710B (zh) * 2012-06-29 2017-09-22 里克思特生物技术有限公司 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯
AU2013282365A1 (en) 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
WO2015175487A1 (en) 2014-05-13 2015-11-19 Novartis Ag Compounds and compositions for inducing chondrogenesis
US20170136008A1 (en) * 2014-06-20 2017-05-18 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
AU2015314753A1 (en) * 2014-09-12 2017-04-06 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
MX2017010654A (es) 2015-02-19 2019-01-30 Lixte Biotechnology Inc Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
EP3294287B1 (en) 2015-05-15 2020-04-08 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
CN109475543A (zh) * 2016-01-27 2019-03-15 利克斯特生物技术公司 用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案
BR112019011627A2 (pt) * 2016-12-08 2019-11-12 Lixte Biotechnology Inc oxabiciclo-heptanos para modulação da resposta imunológica
EP4281063A1 (en) * 2021-01-19 2023-11-29 Lixte Biotechnology, Inc. Oxabicycloheptanes for treatment of small cell lung cancer
WO2022232135A1 (en) * 2021-04-28 2022-11-03 The University Of Toledo Methods of treating cancer and ischemia diseases by inhibition and intervention of atr prolyl isomerization

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957906A (en) 1955-10-25 1960-10-25 Monsanto Chemicals Ketones
US3227473A (en) 1963-12-12 1966-01-04 Julian S Halbern Check identification
JPS5752354B2 (es) 1973-10-22 1982-11-06
JPS5069091U (es) 1973-10-25 1975-06-19
US3980674A (en) 1974-01-28 1976-09-14 Delmar Chemicals Limited 2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene
JPS5132733A (en) 1974-09-10 1976-03-19 Kyowa Hakko Kogyo Kk Josozai
US3954913A (en) 1975-01-06 1976-05-04 The Standard Oil Company Stabilized nitrile polymers
JPS5188631U (es) 1975-01-10 1976-07-15
JPS5188631A (en) 1975-01-31 1976-08-03 Hiiryoyosatsukinzai oyobi sonoseizoho
US4143054A (en) 1977-11-04 1979-03-06 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane- and 7-oxabicycloheptene compounds
US4218478A (en) 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
US4760067A (en) * 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
US4298752A (en) 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4614825A (en) 1982-05-17 1986-09-30 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane and 7-oxabicycloheptene compounds
US4463015A (en) 1982-08-18 1984-07-31 E. R. Squibb & Sons, Inc. Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation
US4518696A (en) * 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US4524151A (en) 1983-11-14 1985-06-18 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane thio ethers useful as cardiovascular agents
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US4654355A (en) 1985-08-01 1987-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs
US4816579A (en) 1986-06-04 1989-03-28 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
US4851553A (en) 1986-06-04 1989-07-25 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane amido-carboxylic acids
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
SU1553533A1 (ru) 1988-01-28 1990-03-30 Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко Способ получени 1,4-бисполифторалкил-7-оксбицикло [2.2.1]гептанов
JP2789365B2 (ja) 1988-12-14 1998-08-20 塩野義製薬株式会社 ジカルボン酸モノエステルおよびその製造法
RU2015980C1 (ru) 1990-02-06 1994-07-15 Е.Р.Сквибб энд Санз, Инк. 7-оксабициклогептилзамещенные гетероциклические амиды или их стереоизомеры в качестве антагонистов рецепторов тромбоксана
US5763647A (en) 1990-03-30 1998-06-09 Shionogi & Co., Ltd. Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives
EP0536163A1 (en) 1990-06-04 1993-04-14 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides
US5266710A (en) 1990-12-18 1993-11-30 Patel Ramesh N (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
JP3134233B2 (ja) * 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
US5326898A (en) 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
US6602713B1 (en) 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5518993A (en) 1994-08-12 1996-05-21 Buckman Laboratories International, Inc. Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endothal and salts thereof
US5770382A (en) 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US6222055B1 (en) 1995-07-06 2001-04-24 Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. Hydrolyzable and polymerizable and/or polyadditive silanes
DE19600707B4 (de) 1996-01-11 2004-02-19 Glüsenkamp, Karl-Heinz, Dr. Biyclische Anhydrid-Wirkstoff-Verbindungen, Verfahren zur Herstellung und Verwendung derselben
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5925651A (en) 1996-04-03 1999-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
DE69842094D1 (de) 1997-10-15 2011-02-17 Polarx Biopharmaceuticals Inc Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
ATE413889T1 (de) 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
US20040110822A1 (en) 1998-07-14 2004-06-10 The University Of Newcastle Research Associates Anhydride modified cantharidin analogues useful in the treatment of cancer
AUPP466598A0 (en) 1998-07-14 1998-08-06 University Of Newcastle Research Associates Limited, The Product and process
IL141063A (en) 1998-08-07 2005-06-19 Applied Research Systems Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
US20020151515A1 (en) 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
US6949624B1 (en) 1999-08-03 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Cloning of the human nuclear receptor co-repressor gene
WO2001018171A2 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US7605185B2 (en) 1999-11-23 2009-10-20 Gerhart Graupner Treatment of arrhythmia by retinoids affecting signal transduction
AU2001243253A1 (en) 2000-02-24 2001-09-03 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
JP4518627B2 (ja) 2000-03-14 2010-08-04 旭化成イーマテリアルズ株式会社 ヒドロキシポリアミド
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
DE10038043B4 (de) 2000-08-02 2006-09-07 Walter, Michael, Dr. Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE300529T1 (de) 2000-09-21 2005-08-15 Smithkline Beecham Plc Imidazolderivate als raf-kinase-inhibitoren
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
WO2002029018A2 (en) 2000-10-06 2002-04-11 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US20020177692A1 (en) 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
WO2002066045A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc. Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
DE10122898A1 (de) * 2001-05-11 2002-11-14 Haarmann & Reimer Gmbh Verwendung von Hydroxyflavanonen zur Maskierung des bitteren Geschmacks
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
CA2456083C (en) 2001-08-03 2012-05-01 John K. Inman Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US7179450B2 (en) 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
EP1443928B1 (en) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
DK1443967T3 (da) 2001-11-06 2007-04-16 Novartis Ag Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor
AU2002353845A1 (en) 2001-11-23 2003-06-10 Eli Lilly And Company Prodrugs of excitatory amino acids
JP2004035408A (ja) * 2002-02-15 2004-02-05 Chiron Corp テザシタビンを含有する安定な組成物
WO2003070754A1 (fr) 2002-02-20 2003-08-28 Minoru Yoshida Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EA013643B1 (ru) 2002-03-08 2010-06-30 Басф Акциенгезельшафт Фунгицидная смесь на базе протиоконазола с тиаметоксамом
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
IL149404A0 (en) 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
AU2003241346A1 (en) 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
WO2003097835A2 (en) 2002-05-16 2003-11-27 Molecular Engines Laboratories Pharmaceutical compositions for the treatment of cancer
CA2499874A1 (en) 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
DE03768629T1 (de) 2002-11-05 2006-01-26 The Regents Of The University Of California, Oakland Verfahren und materialien zur untersuchung von mit glioblastomprogression assoziierten wegen
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20040197888A1 (en) * 2002-12-31 2004-10-07 Armour Christopher D. Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
US20050102708A1 (en) 2003-03-12 2005-05-12 Laurent Lecanu Animal model simulating neurologic disease
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005025620A2 (en) 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
EP1653960A4 (en) 2003-08-13 2008-11-26 Amgen Inc MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
JP4792582B2 (ja) 2003-08-21 2011-10-12 国立大学法人大阪大学 心肥大及びそれに起因する心疾患を予防または治療するための医薬組成物
US7094193B2 (en) 2003-08-28 2006-08-22 Philip Morris Usa Inc. High speed laser perforation of cigarette tipping paper
US20070004771A1 (en) 2003-10-06 2007-01-04 Glaxo Group Limited Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
US20050182011A1 (en) 2003-11-13 2005-08-18 Eric Olson Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
GB0328157D0 (en) 2003-12-04 2004-01-07 Imp College Innovations Ltd Compounds
EP1699436A2 (en) 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US8652502B2 (en) 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
CA2555632A1 (en) 2004-02-02 2005-08-18 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
CN1586500A (zh) 2004-07-19 2005-03-02 俞锋 ***的斑蝥酸钠注射剂及其制备方法
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006052842A2 (en) 2004-11-09 2006-05-18 The Trustees Of The University Of Pennsylvania Methods for diagnosis of myelodysplastic syndromes (mds)
KR100677149B1 (ko) 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
EP1863804A1 (en) 2005-04-01 2007-12-12 Methylgene, Inc. Inhibitors of histone deacetylase
CN1304396C (zh) * 2005-04-08 2007-03-14 中山大学 斑蝥素衍生物及其制备方法
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
WO2007014033A2 (en) 2005-07-22 2007-02-01 The Regents Of The University Of Colorado, A Body Corporate Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
CN101282718A (zh) 2005-08-10 2008-10-08 诺瓦提斯公司 脱乙酰酶抑制剂的使用方法
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
CA2633010A1 (en) 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
WO2007092414A2 (en) 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
JP5554988B2 (ja) 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US20090018142A9 (en) 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20080267947A1 (en) 2006-09-07 2008-10-30 Cirrito Thomas P Cancer therapy with cantharidin and cantharidin analogs
EP2059233B1 (en) 2006-09-08 2013-05-01 Institut Gustave Roussy (IGR) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, and uses therof in combination with etoposide or mitomycin c
US20080097561A1 (en) 2006-10-18 2008-04-24 Medcool, Inc. Dual cycle thermal system and method of use
CA2670259A1 (en) 2006-11-15 2008-05-22 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
US8413445B2 (en) 2007-05-11 2013-04-09 General Electric Company Method and system for porous flame holder for hydrogen and syngas combustion
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
US20090035292A1 (en) 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
JP5730575B2 (ja) 2007-10-01 2015-06-10 リクスト・バイオテクノロジー，インコーポレイテッド Ｈｄａｃ阻害剤
JP5069091B2 (ja) 2007-12-12 2012-11-07 三菱電機株式会社 監視カメラおよび監視カメラシステム
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010014141A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CN101367783A (zh) 2008-10-10 2009-02-18 中国科学技术大学 5-羟甲基糠醛的制备方法
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
US20120135522A1 (en) 2009-06-18 2012-05-31 Kovach John S Methods of modulating cell regulation by inhibiting p53
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
AU2011243947A1 (en) 2010-04-23 2012-12-06 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2012162535A1 (en) 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
SI2857385T1 (sl) 2012-06-01 2017-10-30 Taisho Pharmaceutical Co., Ltd. Predzdravilo amino kisline, ki vsebuje fluor
AU2013282365A1 (en) 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
CN104619710B (zh) 2012-06-29 2017-09-22 里克思特生物技术有限公司 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯
WO2014089279A1 (en) 2012-12-05 2014-06-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
US20160008336A1 (en) 2013-03-05 2016-01-14 Lixte Biotechnology, Inc. Hdac inhibitors for the treatment of traumatic brain injury
WO2014149494A1 (en) 2013-03-15 2014-09-25 Lixte Biotechnology, Inc. Sanguinarine analog pp2c inhibitors for cancer treatment
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
EP3068398A4 (en) 2013-11-15 2017-11-15 Lixte Biotechnology, Inc. Protein phosphatase inhibitors that cross the blood brain barrier
US9051332B1 (en) 2013-11-20 2015-06-09 Transitions Optical, Inc. Photochromic indeno-fused ring pyran compounds
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10071092B2 (en) 2014-04-28 2018-09-11 Alembic Pharmaceuticals Limited Polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
US20170136008A1 (en) 2014-06-20 2017-05-18 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
AU2015314753A1 (en) 2014-09-12 2017-04-06 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
US9994584B2 (en) * 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
MX2017010654A (es) 2015-02-19 2019-01-30 Lixte Biotechnology Inc Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3294287B1 (en) 2015-05-15 2020-04-08 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
MY201101A (en) 2015-09-17 2024-02-05 Novartis Ag Car t cell therapies with enhanced efficacy
CN109475543A (zh) 2016-01-27 2019-03-15 利克斯特生物技术公司 用磷酸酶抑制剂治疗骨髓发育不良综合征的临床方案
BR112019011627A2 (pt) 2016-12-08 2019-11-12 Lixte Biotechnology Inc oxabiciclo-heptanos para modulação da resposta imunológica
US20210275521A1 (en) 2017-12-05 2021-09-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
US20210379106A1 (en) 2018-06-14 2021-12-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function
RU201598U1 (ru) 2020-05-14 2020-12-22 Андрей Владимирович Дмитриев Безреагентная испарительная градирня
EP4281063A1 (en) 2021-01-19 2023-11-29 Lixte Biotechnology, Inc. Oxabicycloheptanes for treatment of small cell lung cancer
US20230310418A1 (en) 2022-01-04 2023-10-05 Lixte Biotechnology, Inc. Compositions and methods for treating cancer or preventing, inhibiting or reducing risk of metastasis of a cancer

Also Published As

Publication number Publication date
CA2909160C (en) 2021-05-25
US20240041864A1 (en) 2024-02-08
US20200179375A1 (en) 2020-06-11
JP2016516772A (ja) 2016-06-09
AU2014251087A1 (en) 2015-11-19
EP2983661A4 (en) 2016-12-21
CN105209036B (zh) 2018-10-26
US10532050B2 (en) 2020-01-14
HK1221416A1 (zh) 2017-06-02
EP2983661B1 (en) 2024-05-29
US11931354B2 (en) 2024-03-19
KR20160004299A (ko) 2016-01-12
EA201591931A1 (ru) 2016-05-31
WO2014168941A1 (en) 2014-10-16
BR112015025852A2 (pt) 2017-07-25
PH12015502331A1 (en) 2016-02-22
AU2014251087B2 (en) 2019-05-02
EP2983661A1 (en) 2016-02-17
CA2909160A1 (en) 2014-10-16
CN105209036A (zh) 2015-12-30
US20160051544A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
PH12015502331A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
PH12019500176A1 (en) Heterocyclic compounds and ther uses
CL2016002772A1 (es) Composiciones de insulina de rápida acción
GEP20217239B (en) Pharmaceutical composition
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
EP3191096A4 (en) Human dosing of phosphatase inhibitor
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
TWD179460S (zh) 機車
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
GEP20217240B (en) Pharmaceutical composition
MX2015012416A (es) Compuestos heterociclicos y sus usos.
IN2013MU03641A (es)
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
IN2014CH00840A (es)
UY35690A (es) Composiciones farmacéuticas de ranolazina y dronedarona
IL253824A0 (en) Pharmaceutical formulations of c1 esterase inhibitor
MX2016006742A (es) Composicion farmaceutica.